Stocksigma LogoStocksigma Logo

Speciality Medicines Reports H1 FY27 Results with Revenue Growth and Zero Tax Provision

Speciality Medicines Limited reported standalone net revenue from operations of ₹8,695.10 lakh for the half-year ended 30th Sep'26, up 185.07% YoY compared

Speciality Medicines Reports H1 FY27 Results with Revenue Growth and Zero Tax Provision

Speciality Medicines Ltd · Outcome · 12 Nov 2026, 9:56 pm

Speciality Medicines Reports H1 FY27 Results with Revenue Growth and Zero Tax Provision Speciality Medicines Limited reported standalone net revenue from operations of ₹8,695.10 lakh for the half-year ended 30th Sep'26, up 185.07% YoY compared to ₹3,050.17 lakh in H1 FY26 and 94.16% QoQ versus ₹4,478.34 lakh in H2 FY26. Net profit rose to ₹888.49 lakh from ₹485.02 lakh in H1 FY26, with basic and diluted EPS at ₹10.11. The company claimed 100% tax deductions under Section 80-IAC as a DPIIT-recognized startup, resulting in zero corporate tax provision. Additionally, ₹1,795.09 lakh of the ₹2,914.00 lakh IPO proceeds were utilized without deviations.

Original exchange filing (PDF)

More announcements from Speciality Medicines Ltd

All Speciality Medicines Ltd announcements